复方甘草酸苷片治疗儿童非酒精性脂肪性肝病疗效观察

发布时间：2018-10-19 15:24

【摘要】：目的探讨复方甘草酸苷片治疗儿童非酒精性脂肪性肝病的临床疗效。方法将2014年6月至2016年5月就诊的65例非酒精性脂肪性肝病患儿随机分为复方甘草酸苷片治疗组(n=33)和护肝片对照治疗组(n=32),分别予以口服复方甘草酸苷片和护肝片治疗24周。两组患儿均于治疗前后检测血清丙氨酶氨基转移酶(ALT)、γ-谷氨酰转肽酶(γ-GT)、透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)和层黏连蛋白(LN)水平。结果复方甘草酸苷片组和护肝片组治疗总有效率分别为85%和50%,两组比较差异有统计学意义(P0.05);两组患儿血清ALT水平治疗后较治疗前均显著下降(P0.05),但复方甘草酸苷片组较护肝片组下降更明显(P0.01);复方甘草酸苷片组治疗后血清γ-GT水平以及肝纤维化四项指标(HA、PCⅢ、CⅣ、LN)水平较治疗前均得到明显改善(P0.05),而护肝片组上述各指标水平较治疗前均无显著变化(P0.05)。结论复方甘草酸苷片可有效改善非酒精性脂肪性肝病患儿的肝功能,并能降低肝纤维化血清学指标水平;其疗效优于护肝片治疗。
[Abstract]:Objective to investigate the clinical effect of compound glycyrrhizin tablets on non-alcoholic fatty liver disease in children. Methods from June 2014 to May 2016, 65 children with non-alcoholic fatty liver disease were randomly divided into two groups: compound glycyrrhizin tablet group (n = 33) and Hugan tablet control group (n = 32). They were treated with compound glycyrrhizin tablet and Hugan tablet for 24 weeks respectively. Serum alanine aminotransferase (ALT), 纬 -glutamyltranspeptidase (纬-GT), hyaluronic acid (HA), type 鈪，

本文编号：2281538